Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease by Yi Sun (118759)

“…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i>_d,RIPK1 = 8.6 nM, <i>K</i>_d,RIPK3 > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC₅₀ = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”

Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease by Yi Sun (118759)

“…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i>_d,RIPK1 = 8.6 nM, <i>K</i>_d,RIPK3 > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC₅₀ = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”

Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease by Yi Sun (118759)

“…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i>_d,RIPK1 = 8.6 nM, <i>K</i>_d,RIPK3 > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC₅₀ = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”

Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease by Yi Sun (118759)

“…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i>_d,RIPK1 = 8.6 nM, <i>K</i>_d,RIPK3 > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC₅₀ = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”

ACT and ISO decrease pathological changes in LPS-induced AKI mice. by Jing Lian (1671991)

Decreased number of cones and retinal ganglion cells in Oc-deficient retina. by Michaela Kreplova (9239560)

siRNA Knockdown of PKCδ decreases phosphorylation of VEEV capsid. by Brian D. Carey (6092747)

Intensity-modulated proton therapy decreases dose to organs at risk in low-grade glioma patients: results of a multicentric <i>in silico</i> ROCOCO trial by Daniëlle B. P. Eekers (5560430)

Knockdown of MYC expression decreases sphere formation in pancreatic ductal cells. by Katsuhiko Sato (1767925)

Umbelliprenin treatment decreases the activity of the TCF reporter in gastric cancer cells. by Lijing Zhang (463702)

Decrease in the interscale differentiation marker in senescence prone SAMP8 mice. by Gopakumar Changarathil (3479078)

Placental aromatase expression decreased in severe neonatal opioid withdrawal syndrome by Courtney Townsel (6705368)

DICER protein expression is significantly decreased in the absence of MOV10 and FMRP. by Monica C. Lannom (11772729)

SUI-sEVs decreased the migration ability of primary cultured fibroblasts. by Xiaoyan Sun (28501)

rHSP60 decreases LPS-induced mononuclear cell proliferation. by Igor Emiliano L. Souza (18196495)

A high-salt high fat diet decreased locomotor activity but did not alter circadian rhythm. by Yoko Yokoyama (394202)

TG6-44 treatment decreases A/X31-induced ROS in THP-1 cells. by Juan A. De La Cruz (11154187)

Datasheet1_Impact of lockdown on children with type-1 diabetes: returning to the community was associated with a decrease in HbA1c.pdf by Benjamin Morat (17677977)

“…No significant difference was observed between medians of HbA1c_mean and HbA1c_after values (8.37% [7.88; 9.32%] vs. 8.50% [7.70; 9.50%], respectively; p = 0.391). …”

Datasheet2_Impact of lockdown on children with type-1 diabetes: returning to the community was associated with a decrease in HbA1c.pdf by Benjamin Morat (17677977)

“…No significant difference was observed between medians of HbA1c_mean and HbA1c_after values (8.37% [7.88; 9.32%] vs. 8.50% [7.70; 9.50%], respectively; p = 0.391). …”

Primary endpoint analysis, i.e., time to first occurrence of combined event of 50% decrease in eGFR or ESRD. by Rozita Mohd (7411322)